Ferric Derisomaltose

Summary

Ferric Derisomaltose (CHEMBL4298187) is an approved oligosaccharide; indicated across 4 conditions including iron deficiency anemia and anemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligosaccharide
• Indications: 4 conditions
• Clinical trials: 22

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298187
Name	Ferric Derisomaltose
Type	Oligosaccharide
Max phase	4

Also known as: Derisomaltosa ferrica, Derisomaltose ferrique, Diafertm, Ferric derisomaltose, Monoferric, Monofartm, Monofertm, Monoferrictm, Monoferrotm, Monovertm, NS32, FERRIC DERISOMALTOSE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
iron deficiency anemia	4	MONDO:0001356	HP:0001891
anemia	4	MONDO:0002280	MONDO:0002280
chronic kidney disease	3	MONDO:0005300	EFO:0003884

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 22.

Phase distribution

Phase	Trials
PHASE4	10
PHASE3	10
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04913649	PHASE4	RECRUITING	Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
NCT05714007	PHASE4	RECRUITING	The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery
NCT05929729	PHASE4	RECRUITING	Iron Deficiency Anemia (IDA) and the Brain
NCT06898814	PHASE4	RECRUITING	The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery
NCT07238972	PHASE4	NOT_YET_RECRUITING	Postoperative Intravenous Ferric Derisomaltose for Prevention of Long-term Anemia After Cardiac Surgery
NCT02642562	PHASE4	COMPLETED	Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN
NCT04608539	PHASE4	COMPLETED	A Clinical Trial Assessing the Efficacy of Intravenous Iron for the Treatment of Anemia Following Cardiac Surgery
NCT05258825	PHASE4	UNKNOWN	Preoperative Monoferric for Abdominal Surgery
NCT05971732	PHASE4	UNKNOWN	The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
NCT05991128	PHASE4	UNKNOWN	The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life
NCT05179226	PHASE3	RECRUITING	Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia
NCT05251493	PHASE3	RECRUITING	Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy
NCT05407987	PHASE3	RECRUITING	Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
NCT05462704	PHASE3	RECRUITING	Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
NCT06929806	PHASE3	RECRUITING	Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT02940860	PHASE3	COMPLETED	Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
NCT02940886	PHASE3	COMPLETED	Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
NCT02962648	PHASE3	COMPLETED	An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
NCT03237065	PHASE3	COMPLETED	Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
NCT03238911	PHASE3	COMPLETED	Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
NCT05763043	EARLY_PHASE1	RECRUITING	Monoferric for Prenatal Iron Deficiency
NCT06542822	Not specified	RECRUITING	IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).